Edition:
United States

Kamada Ltd (KMDA.TA)

KMDA.TA on Tel Aviv Stock Exchange

2,293.00ILa
19 Jan 2017
Change (% chg)

-41.00 (-1.76%)
Prev Close
2,334.00
Open
2,334.00
Day's High
2,334.00
Day's Low
2,257.00
Volume
72,288
Avg. Vol
80,575
52-wk High
2,392.00
52-wk Low
1,310.00

KMDA.TA

Chart for KMDA.TA

About

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes... (more)

Overall

Beta: 0.44
Market Cap(Mil.): ₪828.74
Shares Outstanding(Mil.): 36.42
Dividend: --
Yield (%): --

Financials

  KMDA.TA Industry Sector
P/E (TTM): -- 29.51 30.38
EPS (TTM): -0.42 -- --
ROI: -5.12 15.44 14.86
ROE: -5.63 16.62 16.28

BRIEF-Kamada announces collaboration agreement with Yissum for Development of a Recombinant Human Alpha 1 Antitrypsin

* Press release - Kamada announces collaboration agreement with Yissum for development of a recombinant human Alpha 1 Antitrypsin Source text for Eikon: Further company coverage:

Nov 15 2016

BRIEF-Kamada Q3 loss per share $0.03

* Kamada ltd - reiterates 2016 revenue guidance of $75 to $80 million and 2017 revenue target of $100 million

Nov 10 2016

BRIEF-Kedrion Biopharma and Kamada announce FDA acceptance of BLA submission

* Says FDA has assigned a prescription drug user fee act (PDUFA) goal date of August 29, 2017, for completion of review of BLA

Nov 07 2016

BRIEF-Kedrion Biopharma, Kamada- FDA accepts rabies immunoglobulin review

* Kedrion biopharma and kamada announce fda acceptance of bla submission for human rabies immunoglobulin as a post-exposure treatment Source text for Eikon: Further company coverage:

Nov 07 2016

BRIEF-Kamada announces plan for Phase 2/3 clinical trial with Alpha-1 Antitrypsin IV

* Kamada announces plan for phase 2/3 clinical trial with Alpha-1 antitrypsin iv for treatment of graft-versus-host disease

Nov 02 2016

BRIEF-Migdal Insurance & Financial Holdings reports 5.01 pct passive stake in Kamada

* Migdal Insurance & Financial Holdings Ltd reports 5.01 pct passive stake in Kamada as of September 7, 2016 - SEC filing Source text - http://bit.ly/2c5hTfN Further company coverage:

Sep 12 2016

BRIEF-Kamada and Kedrion seek FDA approval of human rabies immunoglobulin

* Kamada and Kedrion seek FDA approval of human rabies immunoglobulin as a post-exposure treatment

Sep 01 2016

BRIEF-Kamada meets primary endpoint of U.S. Phase 2 study of inhaled Alpha-1 Antitrypsin

* Kamada meets primary endpoint of U.S. Phase 2 study of inhaled Alpha-1 Antitrypsin for the treatment of Alpha-1 Antitrypsin deficiency

Aug 30 2016

BRIEF-Kamada reports Q2 adjusted loss per share $0.11

* Kamada reports financial results for the second quarter and first six months of 2016

Aug 02 2016

Earnings vs. Estimates